Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 7/20 | 0.89 |
| ▸ | LMNA | P02545 | 7/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 3/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | PGR | P06401 | 2/20 | 0.89 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | RECQL | P46063 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.89 |
| ▸ | SHBG | P04278 | 2/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.89 |
| ▸ | HTR2B | P41595 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol SCHEMBL3223253 | 1.00 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL8092599 | 1.00 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL9273501 | 0.94 | ESR1 (0.87) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL5887626 | 0.94 | ESR1 (0.91) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL28211603 | 0.94 | ESR1 (0.95) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL24037697 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL18258335 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL15610005 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL19235633 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL7260525 | 0.94 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2023242235-A1 | ABCG2 INHIBITOR AND NAE INHIBITOR FOR THE TREATMENT OF CANCER | SCANDION ONCOLOGY A/S (DK) | 2023-12-21 | — | — | WO | claimed |
| EP-3089732-B1 | CONTROLLED RELEASE FATTY ACID COMPOSITIONS FOR USE IN BODY RECONSTRUCTION AND BODY-SHAPING | PB&B SA (CH) | 2023-09-27 | — | — | EP | claimed |
| CN-114796236-A | Composition for treating dementia | 史蒂文·霍夫曼 | 2022-07-29 | — | — | CN | claimed |
| US-20220125803-A1 | METHODS FOR THE TREATMENT OF PERIMENOPAUSE AND MENOPAUSE | PRAXIS PRECISION MEDICINES, INC. | 2022-04-28 | — | — | US | claimed |
| EP-3934655-A1 | METHODS FOR THE TREATMENT OF PERIMENOPAUSE AND MENOPAUSE | Praxis Precision Medicines, Inc. (US) | 2022-01-12 | — | — | EP | claimed |
| CN-113891715-A | Peri-and menopausal therapy | 普拉西斯精密医药公司 | 2022-01-04 | — | — | CN | claimed |
| US-20200306261-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF CANCER | UNIV PENNSYLVANIA (US) | 2020-10-01 | — | — | US | claimed |
| CN-105848628-B | Controlled release fatty acid composition for body reconstruction and body shaping | PB&B公司 | 2020-09-18 | — | — | CN | claimed |
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| EP-0500793-B1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORP (US) | 1993-11-03 | — | — | EP | claimed |
| EP-0472645-B1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1993-07-14 | — | — | EP | claimed |
| US-5200197-A | Contraceptive pill | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | claimed |
| EP-0500793-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL. | ALZA CORP (US) | 1992-09-02 | — | — | EP | claimed |
| US-5116865-A | Antifertility Agents | SRI INTERNATIONAL, A CORP OF CA | 1992-05-26 | — | — | US | claimed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | claimed |
| EP-0472645-A1 | OSMOTIC DOSAGE FORM. | ALZA CORP (US) | 1992-03-04 | — | — | EP | claimed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1990014075-A1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1990-11-29 | — | — | WO | claimed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306261-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF CANCER | GPER1, GPR3, GPR4 | ESR1 4/4885LMNA 1750/4885HSD17B10 2650/4885 |
| US-20220125803-A1 | METHODS FOR THE TREATMENT OF PERIMENOPAUSE AND MENOPAUSE | PGR, GPER1, PGRMC1 | ESR1 19/4885LMNA 3484/4885HSD17B10 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.